Phase 2 N=41 Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Chikungunya Virus Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) — 15; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 Chikungunya Virus Vaccine Trial in Healthy Adults
Viral Vaccines · Chikungunya Fever · Chikungunya Virus Infection
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants
Phase 2 N=34 Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
Chikungunya
Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects
Phase 2 N=400 Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Chikungunya Virus Infection
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Injection — 136; 161; 58; 37 Participants
Phase 2 N=263 Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
Chikungunya Virus Infection
Primary: Functional Anti-chikungunya Antibody Titers on Day 56 (28 Days Post Immunisation) Confirmed by Plaque Reduction Neutralization Test (PRNT50) — 50.2; 5.0; 12.9; 5.0 Titer…
Phase 3 N=3,258 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Chikungunya Virus
Primary: Incidence of Solicited Adverse Events (AE) — 319; 373; 366; 124 Participants
Phase 2 N=60 Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Chikungunya
Primary: Percentage of Participants With 4-fold Rise in Anti-CHIKV Neutralizing Antibody Response — 100; 100 percentage of participants — p=1
Phase 2 N=445 Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
Chikungunya Virus Infection
Primary: Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8. — 2057.0; 1116.2; 1465.3; 2023.8 titer — p=0.0015
Phase 2 N=60 Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
Chikungunya Virus Infection
Primary: Geometric Mean Titer of Anti-Chikungunya Antibodies as Measured by 50% Plaque Reduction Neutralization Test 28 Days After Last MV-CHIK Vaccination — 21.0; 19.1; 13.6…
Phase 3 N=4,115 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
Chikungunya Virus Infection
Primary: Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination — 204; 0; 59; 0 Participants
Phase 2 N=25 A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Chikungunya Virus
Primary: CHIKV SNA (Serum Neutralizing Antibody) Seroresponse Rate at Day 22 — 100.0 Percentage of participants
Phase 3 N=408 Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
Chikungunya Virus Infection
Primary: Geometric Mean Titer (GMT) of CHIKV-specific Neutralizing Antibodies as Determined by Microneutralization (μPRNT) Assay in Subjects Who Tested Negative for CHIKV…
N/A N=300 Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants
Phase 3 N=413 Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
Chikungunya Virus
Primary: Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22 in Baseline Seronegative Participants — 87.3; 1.1 percentage of participants — p=<0.0001
Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants
Phase 1 N=56 Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Zika Virus
Primary: Number of Solicited Adverse Events — 1; 0; 0; 0 events
Phase 1 N=10 ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants
Phase 2 N=180 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain Before and Following Injection (Inj.) With CYD Dengue Tetravalent…
Phase 2 N=300 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Percentage of Participants (Aged 2 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or…
N/A N=2,116 Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
Dengue
Primary: Incidence of All Laboratory-confirmed Symptomatic Dengue Infection — 10.5; 11.5 Cases in 1000 person-years
Phase 2 N=56 An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
Dengue
Primary: Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. — 3.00; 5.2; 4.7; 5.0 log10 RNA copies/mL/days
Phase 1 N=42 Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia
Vector Borne Diseases
Primary: Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin — 50; 5 % of total dendritic cells
Phase 2 N=16 VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
Malaria, Vivax
Primary: Efficacy of the ChAd63 and MVA PvDBP Vaccines, Administered in a Heterologous Prime-boost Regimen, Assessed by a Reduced Parasite Multiplication Rate in Vaccinated…
Phase 2 N=189 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Virus Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or…
Phase 2 N=112 Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
West Nile Fever
Primary: Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion). — 0; 21; 36; 27 Participants
N/A N=19 Flavivirus Cross-priming Potential of IMOJEV
Japanese Encephalitis
Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells
N/A N=90 A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
Chikungunya Virus · Dengue Virus
Primary: The Proportion of Transfused INTERCEPT Platelet Components With a Post-treatment Platelet Dose ≥ 3.0×10^11 Platelets. — 256 Platelet Components